Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALL009
MIFTS: 52

Allergic Conjunctivitis

Categories: Eye diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Allergic Conjunctivitis

About this section

MalaCards integrated aliases for Allergic Conjunctivitis:

Name: Allergic Conjunctivitis 12 15 73
Conjunctivitis, Allergic 44
Conjunctivitis Allergic 55

Classifications:

MalaCards categories:
Anatomical: Eye diseases Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:11204
MeSH 44 D003233
NCIt 50 C34506
SNOMED-CT 68 20212001
UMLS 73 C0009766
Sources

Summaries for Allergic Conjunctivitis

About this section
Disease Ontology : 12 A chronic conjunctivitis that is an inflammation of the conjunctiva involing red, itchy, and watery eyes a resulting from an exposure to an allergen or an irritant.

MalaCards based summary : Allergic Conjunctivitis, also known as conjunctivitis, allergic, is related to pollen allergy and giant papillary conjunctivitis. An important gene associated with Allergic Conjunctivitis is RNASE3 (Ribonuclease A Family Member 3), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Alcaftadine and Ephedrine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and t cells, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 76 Allergic conjunctivitis is inflammation of the conjunctiva (the membrane covering the white part of the... more...

Sources

Related Diseases for Allergic Conjunctivitis

About this section

Diseases related to Allergic Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 pollen allergy 31.6 ICAM1 IL13 IL5 RNASE3
2 giant papillary conjunctivitis 31.5 CCL11 CXCL8 IL4 RNASE3
3 allergic rhinitis 30.8 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
4 conjunctivitis 30.3 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
5 vernal keratoconjunctivitis 30.1 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
6 uveitis 29.9 ICAM1 IFNG IL4
7 dermatitis 29.8 CCL11 IFNG IL13 IL4 IL5
8 chlamydia 29.7 CXCL8 IFNG IL4
9 scleritis 29.7 IFNG IL4 IL5
10 rhinitis 29.6 CCL11 CXCL8 HRH1 ICAM1 IL13 IL4
11 atopic keratoconjunctivitis 29.5 IFNG IL4 IL5 RNASE3
12 keratoconjunctivitis 29.3 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
13 asthma 28.6 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
14 dermatitis, atopic 28.1 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
15 loeffler endocarditis 10.2 IL5 RNASE3
16 cytokine deficiency 10.2 IL13 IL5
17 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL13 IL5
18 cow milk allergy 10.2 IL5 RNASE3
19 pemphigoid gestationis 10.2 CCL11 IL5
20 beta-lactam allergy 10.2 IL13 IL4
21 respiratory syncytial virus infectious disease 10.2 IL13 IL5
22 egg allergy 10.2 IL4 IL5
23 sulfamethoxazole allergy 10.2 IL4 IL5
24 gaucher disease, type ii 10.2 IL4 IL5
25 chronic meningitis 10.2 CCL11 IL5
26 trichinosis 10.2 IL4 IL5
27 non-suppurative otitis media 10.2 IL4 IL5
28 diversion colitis 10.2 ICAM1 IL4
29 filarial elephantiasis 10.2 IL4 IL5
30 blepharoconjunctivitis 10.2 CCL11 IL4 RNASE3
31 actinic prurigo 10.2 ICAM1 IL13
32 cough variant asthma 10.2 IL4 IL5 RNASE3
33 intrinsic asthma 10.2 IL4 IL5 RNASE3
34 paragonimiasis 10.2 IL13 IL5 RNASE3
35 milk allergy 10.2 IL4 IL5 RNASE3
36 apple allergy 10.1 IL13 IL4 IL5
37 intestinal schistosomiasis 10.1 IL13 IL4 IL5
38 chronic tic disorder 10.1 IL13 IL4 IL5
39 eosinophilic gastroenteritis 10.1 CCL11 IL5 RNASE3
40 enterobiasis 10.1 IL13 IL4 IL5
41 mikulicz disease 10.1 IL5 PTGDR2
42 dry eye syndrome 10.1
43 bardet-biedl syndrome 15 10.1 ICAM1 IL4
44 esophagitis, eosinophilic, 1 10.1 CCL11 IL13 IL5
45 night blindness, congenital stationary, type 1a 10.1 CCL11 IL13 IL5
46 leukocyte disease 10.1 CCL11 IL4 IL5
47 tungiasis 10.1 CXCL8 IL4
48 bullous pemphigoid 10.1 CCL11 IL5 RNASE3
49 bagassosis 10.1 CXCL8 IL5
50 vulvovaginitis 10.1 CCL11 CXCL8

Graphical network of the top 20 diseases related to Allergic Conjunctivitis:



Diseases related to Allergic Conjunctivitis
Sources

Symptoms & Phenotypes for Allergic Conjunctivitis

About this section

MGI Mouse Phenotypes related to Allergic Conjunctivitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 CCL11 HRH1 ICAM1 IFNG IL13 IL33
2 homeostasis/metabolism MP:0005376 9.81 HRH1 ICAM1 IFNG IL13 IL33 IL4
3 digestive/alimentary MP:0005381 9.8 ICAM1 IFNG IL13 IL33 IL4 IL5
4 immune system MP:0005387 9.65 CCL11 HRH1 ICAM1 IFNG IL13 IL33
5 respiratory system MP:0005388 9.17 CCL11 IFNG IL13 IL33 IL4 IL5
Sources

Drugs & Therapeutics for Allergic Conjunctivitis

About this section

Drugs for Allergic Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 123)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
2
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
3
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6, 75614-87-8 774
4
Pheniramine Approved Phase 4 86-21-5 4761
5
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
6
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
7
Ketotifen Approved Phase 4,Phase 3,Phase 1,Phase 2 34580-14-8, 34580-13-7 3827
8
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
9
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 9865442 444025
10
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-02-2 5743
12
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 1177-87-3
13
Fluticasone Approved, Experimental Phase 4,Phase 2 90566-53-3 62924
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
15
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2 302-25-0
16
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
17
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2 2921-57-5
18
Dipivefrin Approved Phase 4 52365-63-6 3105
19
Desloratadine Approved, Investigational Phase 4 100643-71-8 124087
20
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
21
Montelukast Approved Phase 4 158966-92-8 5281040
22
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
23
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 6447131 17753757
24
Maleic acid Experimental Phase 4 110-16-7 444266
25
Prednisolone hemisuccinate Experimental Phase 4,Phase 2 2920-86-7
26
Tranilast Investigational Phase 4 53902-12-8 93543
27 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Ophthalmic Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29
Histamine Phosphate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-74-1 65513
30 Histamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
32 Nasal Decongestants Phase 4,Phase 3,Phase 2
33 Adrenergic Agents Phase 4,Phase 3,Phase 2
34 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Adrenergic Agonists Phase 4,Phase 3,Phase 2
38 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
39 Respiratory System Agents Phase 4,Phase 3,Phase 2
40 Histamine H1 Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Antipruritics Phase 4,Phase 3,Phase 1,Phase 2
42 Immunologic Factors Phase 4,Phase 3,Phase 2
43 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
45 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Histamine H1 Antagonists, Non-Sedating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Olopatadine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
5 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
6 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
7 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
8 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
9 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
10 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
11 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
12 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
13 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
14 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
15 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
16 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
17 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
18 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
19 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
20 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
21 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
22 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
23 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
24 A Study to Evaluate the Efficacy of Lastacaft® Compared to Patadayâ„¢ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
25 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
26 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
27 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
28 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
29 The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing Completed NCT01128556 Phase 4 Bepreve;Refresh Tears
30 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
31 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone
32 Montelukast as a Controller of Atopic Syndrome Completed NCT00559546 Phase 4 montelukast
33 Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis Recruiting NCT03186755 Phase 4 Hyaluronic acid 0.05% & Ectoine 2.0%;Olopatadine hydrochloride ophthalmic solution 0.1%
34 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Active, not recruiting NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
35 Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan Terminated NCT00276445 Phase 4 beta-1,3-glucan
36 Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification Terminated NCT00124709 Phase 4 Pimecrolimus;Corticosteroid
37 Comparison of CL Wear Between Two Allergy Drops Withdrawn NCT00489398 Phase 4 epinastine HCL and olopatadine HCL
38 A Multicenter Study to Evaluate Safety and Efficacy of Specific Immunotherapy With Modified Allergen Extracts Unknown status NCT01012752 Phase 3
39 Use of Probiotic Bacteria in Prevention of Allergic Disease in Children 1999-2008 Unknown status NCT00298337 Phase 2, Phase 3 Mixture of probiotic bacteria and prebiotic oligosaccharide
40 A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis Completed NCT02492321 Phase 3 EBI-005;Placebo Comparator
41 Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model Completed NCT01479374 Phase 3 AL-4943A ophthalmic solution;AL-4943A vehicle;Olopatadine hydrochloride ophthalmic solution, 0.2%
42 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in Allergic Conjunctivitis Completed NCT00432757 Phase 3 Ketotifen with a Contact Lens (generic name not yet established)
43 Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis Completed NCT00445874 Phase 3 Ketotifen with a Contact Lens (no generic name)
44 Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis Completed NCT00364091 Phase 3 R89674 0.025% ophthalmic solution
45 Evaluation of Efficacy of Ophthalmic Solution in Induced Allergic Conjunctivitis Completed NCT00244543 Phase 3 R89674 (generic name not yet established)
46 Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis Completed NCT00241319 Phase 3 R89674 (generic name not yet established)
47 ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis Completed NCT03494504 Phase 3 Reproxalap Ophthalmic Solution (0.25%);Reproxalap Ophthalmic Solution (0.5%);Vehicle Ophthalmic Solution
48 Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis Completed NCT01743027 Phase 3 AL-4943A ophthalmic solution;Olopatadine hydrochloride ophthalmic solution, 0.2%;Olopatadine hydrochloride ophthalmic solution, 0.1%;AL-4943A ophthalmic solution vehicle
49 A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis Completed NCT01363713 Phase 3 DE-114 ophthalmic solution
50 OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Completed NCT02988882 Phase 3 Dexamethasone

Search NIH Clinical Center for Allergic Conjunctivitis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: conjunctivitis, allergic

Sources

Genetic Tests for Allergic Conjunctivitis

About this section
Sources

Anatomical Context for Allergic Conjunctivitis

About this section

MalaCards organs/tissues related to Allergic Conjunctivitis:

41
Eye, Testes, T Cells, Skin, B Cells, Lung, Bone
Sources

Publications for Allergic Conjunctivitis

About this section

Articles related to Allergic Conjunctivitis:

(show top 50) (show all 633)
# Title Authors Year
1
Variation in the TEK gene is not associated with asthma but with allergic conjunctivitis. ( 29667338 )
2018
2
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. ( 29615844 )
2018
3
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. ( 29543548 )
2018
4
Allergic conjunctivitis: current concepts on pathogenesis and management. ( 29552874 )
2018
5
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression. ( 29398596 )
2018
6
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. ( 29392313 )
2018
7
Tear osteopontin level and its relationship with local Th1/Th2/Th17/Treg cytokines in children with allergic conjunctivitis. ( 29279263 )
2018
8
Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. ( 29432811 )
2018
9
Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. ( 29782067 )
2018
10
Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis. ( 29719638 )
2018
11
Effect of PycnogenolAr on an experimental rat model of allergic conjunctivitis. ( 29675725 )
2018
12
DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs. ( 30051467 )
2018
13
Allergy and Asthma: Allergic Rhinitis and Allergic Conjunctivitis. ( 30152668 )
2018
14
Mini-monoka stenting for patients with perennial allergic conjunctivitis. ( 30204032 )
2018
15
Neuropathic Pain and Itch Mechanisms Underlying Allergic Conjunctivitis. ( 30222114 )
2018
16
Investigation of possible risk factors in the development of seasonal allergic conjunctivitis. ( 30225226 )
2018
17
Oral Immunotherapy for Allergic Conjunctivitis Using Transgenic Rice Expressing Hypoallergenic Antigens. ( 30252684 )
2018
18
Efficacy and Tolerability of Ketotifen in the Treatment Of Seasonal Allergic Conjunctivitis: Comparison between Ketotifen 0.025% and 0.05% Eye Drops. ( 30303746 )
2018
19
Dietary omega-3 fatty acids alter the lipid mediator profile and alleviate allergic conjunctivitis without modulating Th2 immune responses. ( 30383446 )
2018
20
Periostin deletion suppresses late-phase response in mouse experimental allergic conjunctivitis. ( 30420208 )
2018
21
IL-27 Signaling Deficiency Develops Th17-enhanced Th2-dominant Inflammation in Murine Allergic Conjunctivitis Model. ( 30515838 )
2018
22
An inhibitor peptide of toll-like receptor 2 shows therapeutic potential for allergic conjunctivitis. ( 28246054 )
2017
23
Nitrite, neopterin levels and tryptophan degradation in allergic conjunctivitis. ( 28779270 )
2017
24
Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis. ( 28831678 )
2017
25
Role of CCL7 in Type I Hypersensitivity Reactions in Murine Experimental Allergic Conjunctivitis. ( 27956527 )
2017
26
Model for Studying Anti- Allergic Drugs for Allergic Conjunctivitis in Animals. ( 28848937 )
2017
27
Risk of allergic conjunctivitis in patients with type 1 diabetes mellitus: a population-based retrospective cohort study. ( 28630085 )
2017
28
Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis. ( 28652694 )
2017
29
Topical ocular treatment with monoclonal antibody Fab fragments targeting Japanese cedar pollen Cry j 1 inhibits Japanese cedar pollen-induced allergic conjunctivitis in mice. ( 28119075 )
2017
30
Redness response phenotypes of allergic conjunctivitis in an allergen challenge chamber. ( 28007090 )
2017
31
Correction: Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28245290 )
2017
32
Olopatadine hydrochloride ophthalmic solution for the treatment of allergic conjunctivitis. ( 28656804 )
2017
33
Increased red cell distribution width levels in children with seasonal allergic conjunctivitis. ( 28523524 )
2017
34
Effects of Exposure to Ozone on the Ocular Surface in an Experimental Model of Allergic Conjunctivitis. ( 28046113 )
2017
35
Self-Reported Allergic Rhinitis and/or Allergic Conjunctivitis Associate with IL13 rs20541 Polymorphism in Finnish Adult Asthma Patients. ( 28273659 )
2017
36
Efficacy of oral immunotherapy with a rice-based edible vaccine containing hypoallergenic Japanese cedar pollen allergens for treatment of established allergic conjunctivitis in mice. ( 28676431 )
2017
37
Diagnosis and management of allergic conjunctivitis in pediatric patients. ( 28052798 )
2017
38
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment. ( 29026285 )
2017
39
Novel oleyl amine-modified polymannuronic acid micelle loading tacrolimus for therapy of allergic conjunctivitis. ( 28655660 )
2017
40
Allergic Conjunctivitis in Patients with Respiratory Allergic Symptoms; a Retrospective Study in Greece. ( 28428968 )
2017
41
Clinical implications of mast cell involvement in allergic conjunctivitis. ( 29105783 )
2017
42
MiR-146a overexpression effectively improves experimental allergic conjunctivitis through regulating CD4(+)CD25(-)T cells. ( 28810531 )
2017
43
Superoxide dismutase 3 attenuates experimental Th2-driven allergic conjunctivitis. ( 28063939 )
2017
44
Allergic conjunctivitis in Asia. ( 28487836 )
2017
45
Effect of Mandarin Orange Yogurt on Allergic Conjunctivitis Induced by Conjunctival Allergen Challenge. ( 28593244 )
2017
46
Validity of Specific Immunoglobulin E Assay in Tear Film for Detection of Allergens Inducing Different Types of Allergic Conjunctivitis. ( 29528586 )
2017
47
Allergic conjunctivitis. ( 29849438 )
2017
48
Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study. ( 27869354 )
2016
49
TRPV1 Antagonist Suppresses Allergic Conjunctivitis in a Murine Model. ( 27726468 )
2016
50
Topical Administration of I^-1,3-Glucan to Modulate Allergic Conjunctivitis in a Murine Model. ( 27002295 )
2016
Sources

Variations for Allergic Conjunctivitis

About this section
Sources

Expression for Allergic Conjunctivitis

About this section
Search GEO for disease gene expression data for Allergic Conjunctivitis.
Sources

Pathways for Allergic Conjunctivitis

About this section

Pathways related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.89 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
2
PEDF Induced Signaling 64
Show member pathways
 13.55 CCL11 CXCL8 IFNG IL13 IL33 IL4
3
TGF-Beta Pathway 64
Show member pathways
 13.43 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
4
Akt Signaling 64
Show member pathways
 13.29 CCL11 CXCL8 IL13 IL4 IL5 TLR3
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.26 CCL11 CXCL8 ICAM1 IFNG IL13 IL33
6
Pathways in cancer 37
12.75 CXCL8 IFNG IL13 IL4 IL5
7
Influenza A 37
Show member pathways
 12.71 CXCL8 ICAM1 IFNG IL13 IL33 IL4
8
Allograft rejection 1 37
Show member pathways
 12.66 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
9
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 66
Show member pathways
 12.64 CXCL8 IFNG IL33 TLR3
10
Th17 cell differentiation 37
Show member pathways
 12.5 IFNG IL13 IL4 IL5
11
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.32 IFNG IL13 IL4 IL5
12
IL-17 Family Signaling Pathways 65
Show member pathways
 12.24 CCL11 CXCL8 IFNG IL13 IL4 IL5
13
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.2 CXCL8 IFNG IL13 IL4 IL5
14
Bacterial infections in CF airways 22
Show member pathways
 12.13 CCL11 CXCL8 IFNG IL4
15
Necroptosis 37
Show member pathways
 12.1 IFNG IL33 TLR3
16
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 22
Show member pathways
 12.09 CCL11 CXCL8 ICAM1 TLR3
17
Interleukin-4 and 13 signaling 66
11.97 CCL11 CXCL8 ICAM1 IL13 IL4
18
Spinal Cord Injury 1
11.96 CXCL8 ICAM1 IFNG IL4
19
Immune response IFN gamma signaling pathway 22
Show member pathways
 11.96 CCL11 CXCL8 ICAM1 IFNG IL13 IL4
20
Microglia Activation During Neuroinflammation: Overview 65
Show member pathways
 11.95 IFNG IL13 IL4
21
MAPK Pathway 72
Show member pathways
 11.94 IL13 IL5 TLR3
22
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.94 IFNG IL4 IL5 PTGDR2
23
Rheumatoid arthritis 37
11.79 CXCL8 ICAM1 IFNG
24
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.75 CXCL8 IFNG IL4 IL5
25
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.71 CCL11 IFNG IL13 IL4
26
IL4-mediated signaling events 1
11.61 CCL11 IL4 IL5
27
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.61 CXCL8 ICAM1 IFNG
28
Lung fibrosis 1
11.57 CCL11 CXCL8 IL13 IL4 IL5
29
Glucocorticoid receptor regulatory network 1
11.55 CXCL8 ICAM1 IFNG IL13 IL4 IL5
30
Interleukin-10 signaling 66
11.52 CXCL8 ICAM1 IL13 IL4
31
Malaria 37
11.49 CXCL8 ICAM1 IFNG
32
Immune response_Role of integrins in NK cells cytotoxicity 22
11.44 CXCL8 ICAM1 IFNG
33
Innate Lymphoid Cell Differentiation Pathways 65
11.34 IFNG IL13 IL33 IL4 IL5 PTGDR2
34
Inflammatory Response Pathway 1
11.3 IFNG IL4 IL5
35
Cytokines and Inflammatory Response 1
11.26 IFNG IL13 IL4 IL5
36
OX40 Pathway 64
11.17 IFNG IL13 IL4 IL5
37
G-protein signaling_RhoB regulation pathway 22
11.16 CCL11 CXCL8 IL13 IL4 IL5
38
Development and heterogeneity of the ILC family 1
11.16 IFNG IL13 IL33 IL4 IL5
39
IL12 signaling mediated by STAT4 1
11.13 IFNG IL13
40
IL1 and megakaryocytes in obesity 1
11.08 ICAM1 IFNG
41
G-protein signaling_Rap2B regulation pathway 22
10.94 CCL11 CXCL8 IL13 IL4 IL5
42
Th2 Differentiation Pathway 65
10.76 CCL11 IFNG IL13 IL33 IL4 IL5
Sources

GO Terms for Allergic Conjunctivitis

About this section

Cellular components related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular GO:0005622 9.63 CCL11 CXCL8 IFNG IL5 PTGDR2 TLR3
2 extracellular region GO:0005576 9.56 CCL11 CXCL8 IFNG IL13 IL33 IL4
3 extracellular space GO:0005615 9.32 CCL11 CXCL8 ICAM1 IFNG IL13 IL33

Biological processes related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.83 IFNG IL13 IL33 IL4 TLR3
2 defense response to virus GO:0051607 9.79 IFNG IL33 TLR3
3 chemotaxis GO:0006935 9.77 CCL11 CXCL8 PTGDR2
4 positive regulation of angiogenesis GO:0045766 9.76 CCL11 CXCL8 TLR3
5 cellular response to tumor necrosis factor GO:0071356 9.73 CCL11 CXCL8 ICAM1
6 inflammatory response GO:0006954 9.73 CCL11 CXCL8 HRH1 IL13 IL5 TLR3
7 response to virus GO:0009615 9.72 CCL11 IFNG TLR3
8 cellular response to interferon-gamma GO:0071346 9.7 CCL11 ICAM1 TLR3
9 cellular response to interleukin-1 GO:0071347 9.67 CCL11 CXCL8 ICAM1
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 IFNG IL13 IL4
11 extrinsic apoptotic signaling pathway GO:0097191 9.63 IFNG IL33 TLR3
12 cytokine-mediated signaling pathway GO:0019221 9.63 CCL11 CXCL8 ICAM1 IL13 IL4 IL5
13 positive regulation of vasoconstriction GO:0045907 9.62 HRH1 ICAM1
14 positive regulation of interleukin-12 production GO:0032735 9.61 IFNG TLR3
15 negative regulation of osteoclast differentiation GO:0045671 9.61 IL4 TLR3
16 eosinophil chemotaxis GO:0048245 9.59 CCL11 HRH1
17 microglial cell activation GO:0001774 9.58 IL13 TLR3
18 positive regulation of macrophage activation GO:0043032 9.57 IL13 IL33
19 positive regulation of immunoglobulin secretion GO:0051024 9.54 IL33 IL5
20 positive regulation of B cell proliferation GO:0030890 9.54 IL13 IL4 IL5
21 positive regulation of interleukin-13 production GO:0032736 9.51 IL33 IL4
22 negative regulation of endothelial cell apoptotic process GO:2000352 9.5 ICAM1 IL13 IL4
23 immune response GO:0006955 9.5 CCL11 CXCL8 IFNG IL13 IL4 IL5
24 negative regulation of complement-dependent cytotoxicity GO:1903660 9.4 IL13 IL4
25 regulation of signaling receptor activity GO:0010469 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4

Molecular functions related to Allergic Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL11 CXCL8 IFNG IL13 IL33 IL4
2 cytokine receptor binding GO:0005126 8.96 IL13 IL4
Sources

Sources for Allergic Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....